Day: April 30, 2026

In the complex landscape of pediatric nutrition, the stability of the infant formula market remains a paramount concern for both federal regulators and industry stakeholders. Recent years have demonstrated that even minor supply chain disruptions can lead to significant public health crises and socioeconomic volatility. To fortify consumer confidence and ensure product integrity, the FDA has prioritized rigorous oversight through … Read more

The traditional drug development lifecycle has long been characterized by a punctuated equilibrium—long periods of intense activity followed by a “regulatory hiatus” where data sits idle during submission prep. For pharmaceutical executives and regulatory leads, this delay represents not just a cost center, but a barrier to patient access for life-saving therapies. The FDA is now actively dismantling … Read more